Twist Bioscience Corporation (NASDAQ: TWST), a company that provides synthetic DNA using its silicon platform, has announced a strategic collaboration with LakePharma Inc, a US-based biologics company.
It was reported on Friday that the collaboration is aimed at offering antibody discovery and development solutions to pharmaceutical and biotechnology customers.
According to the terms of the contract, LakePharma will have the ability to offer Twist's proprietary antibody discovery and optimisation platforms to its existing and future biopharmaceutical customers as part of its service offerings. One such platform generated is for discovery of novel therapeutic antibodies against a major class of protein drug targets known as GPCRs, which traditionally have been difficult for biologics drug development. GPCRs have been heavily investigated due to their involvement in multiple disease classes, including inflammation, cancer, metabolism, respiratory, and pain.
In return, Twist customers will have access to LakePharma's integrated discovery and development services.
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Genprex increases sites for Acclaim-3 clinical trial
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib